eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 17
Original paper

Histamine 2 receptor antagonists do not improve the outcomes of hospitalized COVID-19 patients

Waseem Amjad
Faisal Kamal
Adnan Malik
Ritu Singh
4, 5
Sultan Mahmood

Department of Internal Medicine, Albany Medical Center, Albany, NY, USA
Department of Gastroenterology, University of Tennessee, Memphis, TN, USA
Department of Internal Medicine, Loyola University Medical Center, Chicago, IL, USA
Department of Internal Medicine, University of Indiana, Fort Wayne, IN, USA
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Department of Gastroenterology, University at Buffalo, Buffalo, NY, USA
Gastroenterology Rev 2022; 17 (2): 146–151
Online publish date: 2021/07/14
View full text Get citation
PlumX metrics:
Some observational studies have demonstrated the benefit of famotidine in COVID-19-infected individuals. The preference of using an H2 receptor antagonist (H2RA) over proton pump inhibitors (PPI) during the COVID-19 pandemic has been questioned by clinicians.

To compare the outcomes of hospitalized patients who were taking H2RA vs. PPI.

Material and methods
We conducted a retrospective review of patients admitted for COVID-19 infection from 1 March until 31 July 2020. We included 396 patients admitted during the study period. Of the total, 39 (9.8%) received H2RA and 86 (21.7%) were taking PPI as home medications; 6 patients were taking both H2RA and PPI.

The baseline characteristics and comorbid conditions were similar in both groups. The mean age was 57.79 ±17.36 years, 43.2% were female, and 48.7% were Caucasian. The common comorbid conditions included HTN (56.8%), obesity (44.4%), diabetes mellitus (38.6%), and coronary artery disease (30.1%). Smoking was more prevalent in the PPI group (42.5% vs. 18.2%, p = 0.03). Gastrointestinal symptoms were seen on initial presentation in 31.1%, and 43.9% had elevated liver enzymes. The H2RA group had similar mortality (HR = 0.84, 95% CI: 0.35–2.05) to the non-H2B group. It remained non-significant as compared to PPI (HR = 0.34–3.19, 95% CI: 0.34–3.19). The secondary outcomes including readmission, ICU admission, and severe COVID infections (including ARDS and thromboembolism) were similar in these groups.

The H2 receptor antagonist used as a home medication did not show benefit over the PPI in patients admitted for COVID-19 infections.


coronavirus disease 2019, H2 receptor blocker, proton pump inhibitors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.